stockportfolio.pro
Mesa Laboratories, Inc. (MLAB)
Technology · Scientific & Technical Instruments · NasdaqGS
Mesa Laboratories, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $93.67M | $96.18M | $103.14M | $117.69M | $133.94M | $184.34M | $219.08M | $216.19M | $240.98M | $249.13M |
| Gross profit | $53.24M | $54.62M | $60.92M | $65.36M | $87.01M | $109.09M | $133.69M | $133.25M | $150.87M | $158.27M |
| Net income | $0 | $0 | $0 | $0 | $3.27M | $1.87M | $930,000 | $-254.25M | $-1.97M | $6.71M |
| Net margin | 0.0% | 0.0% | 0.0% | 0.0% | 2.4% | 1.0% | 0.4% | -117.6% | -0.8% | 2.7% |
Source: Mesa Laboratories, Inc. SEC filings (10-K). 16 years of history available in the interactive view.
What growth is priced into MLAB stock?
At today's market cap of $576.49M, Mesa Laboratories, Inc. is priced for free-cash-flow growth of about 3.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $39.58M from the FY ending 2026-03-31). For comparison, free cash flow actually grew 2.4%/yr over the last five fiscal years and revenue 13.2%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 16 years of Mesa Laboratories, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MLAB in your portfolio →
Mesa Laboratories, Inc. financial history by metric
About Mesa Laboratories, Inc.
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides sterility assurance testing and laboratory services to the dental and pharmaceutical industries. The Biopharmaceutical Development segment develops, manufactures, sells, and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for hereditary disease screenings, pharmacogenetics, oncology related applications, and toxicology research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; and PurePep Symphony and Chorus instruments for peptide synthesis. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as renal care, gas flow, environmental and process monitoring, and torque testing in pharmaceutical, laboratory, medical device, manufacturing, industrial, and environmental applications. This segment's products include continuous monitoring systems, data loggers, and torque testing systems under the DialyGuard, DryCal, DataTrace, and ViewPoint brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.
Mesa Laboratories, Inc. — frequently asked questions
What is Mesa Laboratories, Inc.'s revenue?
Mesa Laboratories, Inc. (MLAB) reported revenue of $249.13M for fiscal year 2026, up 3.4% from the prior year, according to its SEC filings.
Is Mesa Laboratories, Inc. profitable?
Yes. MLAB earned net income of $6.71M in fiscal 2026, a net margin of 2.7%.
What is MLAB's P/E ratio?
Mesa Laboratories, Inc. trades at a price-to-earnings ratio of about 86.2 based on the latest data in our nightly-refreshed cache.
How fast is Mesa Laboratories, Inc. growing?
MLAB's revenue grew at roughly 13.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Mesa Laboratories, Inc. have?
As of fiscal year 2026, MLAB carried roughly $151.48M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Mesa Laboratories, Inc.'s gross margin?
MLAB's gross margin was 63.5% in fiscal 2026 — gross profit of $158.27M on revenue of $249.13M.
What is Mesa Laboratories, Inc.'s market cap?
Mesa Laboratories, Inc. (MLAB) has a market capitalization of about $576.49M, based on the latest data in our nightly-refreshed cache.
When does Mesa Laboratories, Inc.'s fiscal year end?
MLAB's fiscal year ends in March. Its most recent annual filing covers the fiscal year ending 2026-03-31.
What growth is priced into MLAB stock?
At today's market cap of $576.49M, Mesa Laboratories, Inc. is priced for free-cash-flow growth of about 3.4% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $39.58M from the FY ending 2026-03-31). For comparison, free cash flow actually grew 2.4%/yr over the last five fiscal years and revenue 13.2%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Mesa Laboratories, Inc.'s official SEC filings (10-K and 10-Q), covering 16 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.